Dilan Gezer
Dilan Gezer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aslı KUTLU
1 shared publicationAtıf Koca
1 shared publication- Eda Dagsuyu
Istanbul University-Cerrahpasa
1 shared publication - Elifnur Gizem Yildirim
Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, İstinye University, Istanbul 34010, Türkiye
1 shared publication - Engin Ulukaya
Istinye University, Molecular Cancer Research Center (ISUMKAM), Istanbul, Turkey;Istinye University Faculty of Medicine, Department of Biochemistry, Istanbul, TÜRKİYE, Turkey (Türkiye)
1 shared publication Kaan Adacan
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by Elsevier in SSRN Electronic Journal
Novel 1H-Pyrrole-2,5-Dione derivatives as potential Anti-Diabetic Agents: Design, Synthesis, in vitro, in Ovo, and Molecular Docking Studies
Diabetes mellitus (DM) is the most common metabolism-related health problem across the world and new therapeutics are still emerging into the market. One of the treatments is the inhibition of α-glucosidase, which is a validated therapeutic strategy for mitigating postprandial hyperglycemia in Type 2 DM. However, the clinical utility of current inhibitors, such as Acarbose, is often limited by gastrointestinal side effects and suboptimal pharmacokinetics linked to their surface-binding modes. In this study, we reported the design, synthesis, and biological evaluation of a novel series of 1H-Pyrrole-2,5-dione derivatives, targeting the deep catalytic cleft of human acid α-glucosidase (rhGAA). In vitro studies revealed that all the new compounds showed higher enzyme inhibitory activity than Acarbose (IC50 = 54.14 ± 6.43 mM). In in ovo model, compound 3d worked best to reduce blood glucose levels (around 48 mg/mL) and maintained this effect within 3 hours. Molecular docking calculations covering the whole protein surface confirmed the catalytic pocket as the primary binding site, followed by focused docking, which identified 3g as the top in silico hit (-9.35 kcal/mol). In vitro kinetic experiments revealed that 5c possessed the highest inhibitory potential (IC50 = 0.21 mM) and performed significantly better than Acarbose, while structural dynamics analysis of 5c highlighted its conformational instability. Consequently, compound 3d (IC50 = 0.64 mM) was selected as the lead candidate to effectively inhibit rhGAA. Structural fingerprinting elucidated a unique "Anchor Mechanism" for 3d, characterized by a critical hydrogen bond with ARG281.
- 31 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel 1H-Pyrrole-2,5-Dione derivatives as potential Anti-Diabetic Agents: Design, Synthesis, in vitro, in Ovo, and Molecular Docking Studies
Diabetes mellitus (DM) is the most common metabolism-related health problem across the world and new therapeutics are still emerging into the market. One of the treatments is the inhibition of α-glucosidase, which is a validated therapeutic strategy for mitigating postprandial hyperglycemia in Type 2 DM. However, the clinical utility of current inhibitors, such as Acarbose, is often limited by gastrointestinal side effects and suboptimal pharmacokinetics linked to their surface-binding modes. In this study, we reported the design, synthesis, and biological evaluation of a novel series of 1H-Pyrrole-2,5-dione derivatives, targeting the deep catalytic cleft of human acid α-glucosidase (rhGAA). In vitro studies revealed that all the new compounds showed higher enzyme inhibitory activity than Acarbose (IC50 = 54.14 ± 6.43 mM). In in ovo model, compound 3d worked best to reduce blood glucose levels (around 48 mg/mL) and maintained this effect within 3 hours. Molecular docking calculations covering the whole protein surface confirmed the catalytic pocket as the primary binding site, followed by focused docking, which identified 3g as the top in silico hit (-9.35 kcal/mol). In vitro kinetic experiments revealed that 5c possessed the highest inhibitory potential (IC50 = 0.21 mM) and performed significantly better than Acarbose, while structural dynamics analysis of 5c highlighted its conformational instability. Consequently, compound 3d (IC50 = 0.64 mM) was selected as the lead candidate to effectively inhibit rhGAA. Structural fingerprinting elucidated a unique "Anchor Mechanism" for 3d, characterized by a critical hydrogen bond with ARG281.